Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial

BACKGROUND. For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 00...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Oizumi, Satoshi, Kobayashi, Kunihiko, Inoue, Akira, Maemondo, Makoto, Sugawara, Shunichi, Yoshizawa, Hirohisa, Isobe, Hiroshi, Harada, Masao, Kinoshita, Ichiro, Okinaga, Shoji, Kato, Terufumi, Harada, Toshiyuki, Gemma, Akihiko, Saijo, Yasuo, Yokomizo, Yuki, Morita, Satoshi, Hagiwara, Koichi, Nukiwa, Toshihiro
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Lung Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3380886/
https://ncbi.nlm.nih.gov/pubmed/22581822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0426
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky